Swathi Rayasam, Saba Javed
Suzetrigine selectively blocks the NaV1.8 voltage-gated sodium channel in peripheral neurons. Trigeminal neuralgia (TN) is a neuropathic pain syndrome affecting the trigeminal nerve and is traditionally treated with nonselective sodium channel blockers. No studies have evaluated Suzetrigine for TN, but potential involvement of NaV1.8 in TN signaling may represent a novel therapeutic target. We describe four patients with varying symptomatology of TN and previously failed responses to pharmacological and interventional treatments who exhibited notable symptomatic improvements with Suzetrigine, with no adverse effects. Further study is required in larger populations regarding the safety and efficacy of long-term Suzetrigine use for refractory TN.